Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) FCF Margin (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed FCF Margin for 6 consecutive years, with 616.68% as the latest value for Q4 2025.

  • Quarterly FCF Margin fell 24219.0% to 616.68% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 625.62% through Dec 2025, up 50170.0% year-over-year, with the annual reading at 625.62% for FY2025, 50170.0% up from the prior year.
  • FCF Margin hit 616.68% in Q4 2025 for Insight Molecular Diagnostics, up from 2135.38% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 208.02% in Q4 2021 to a low of 18291.04% in Q3 2022.
  • Historically, FCF Margin has averaged 2908.93% across 5 years, with a median of 1484.29% in 2023.
  • Biggest five-year swings in FCF Margin: skyrocketed 4226259bps in 2021 and later plummeted -1713485bps in 2022.
  • Year by year, FCF Margin stood at 208.02% in 2021, then crashed by -1733bps to 3813.87% in 2022, then soared by 61bps to 1492.99% in 2023, then surged by 75bps to 374.5% in 2024, then tumbled by -65bps to 616.68% in 2025.
  • Business Quant data shows FCF Margin for IMDX at 616.68% in Q4 2025, 2135.38% in Q3 2025, and 1279.54% in Q2 2025.